Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR)

被引：2
|
作者：
Ozaki, Y.
Kitano, S.
Matsumoto, K.
Takahashi, M.
Mukohara, T.
Futamura, M.
Masuda, N.
Tsurutani, J.
Yoshimura, K.
Minami, H.
Takano, T.
机构：
[1] Toranomon Gen Hosp, Tokyo, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[4] NHO Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Gifu Univ, Gifu, Japan
[7] NHO Osaka Natl Hosp, Osaka, Japan
[8] Kindai Univ, Osaka, Japan
[9] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[10] Kobe Univ, Sch Med, Kobe, Hyogo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT1-12-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-02
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials
    Wang, Xuan
    Huang, Chun
    Li, Man
    Gu, Yanjun
    Cui, Yanfen
    Li, Yan
    TUMOR BIOLOGY, 2014, 35 (05) : 4841 - 4848
  • [32] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION
    Kourea, H. P.
    Koutras, A. K.
    Kotoula, V.
    Bobos, M.
    Fountzila, A. Kalogera
    Papazisis, K. T.
    Christodoulou, C.
    Res, E.
    Bournakis, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 104 - 104
  • [33] First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
    Miles, D. W.
    Dieras, V.
    Cortes, J.
    Duenne, A. -A.
    Yi, J.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2773 - 2780
  • [34] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Petitjean, Audrey
    Smith-Palmer, Jayne
    Valentine, William
    Tehard, Bertrand
    Roze, Stephane
    BMC CANCER, 2019, 19 (1)
  • [35] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Audrey Petitjean
    Jayne Smith-Palmer
    William Valentine
    Bertrand Tehard
    Stephané Roze
    BMC Cancer, 19
  • [36] HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors
    Deblock, M.
    Esterni, B.
    Tarpin, C.
    Charaffe-Jauffret, E.
    Extra, J. M.
    Viens, P.
    Goncalves, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
  • [38] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Tamura, Kenji
    Inoue, Kenichi
    Masuda, Norikazu
    Takao, Shintaro
    Kashiwaba, Masahiro
    Tokuda, Yutaka
    Iwata, Hiroji
    Yamamoto, Naohito
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakayama, Takahiro
    Sato, Nobuaki
    Toyama, Tatsuya
    Ishida, Takanori
    Arioka, Hitoshi
    Saito, Mitsue
    Ohno, Shinji
    Yamauchi, Hideko
    Yamada, Kimito
    Watanabe, Junichiro
    Ishiguro, Hiroshi
    Fujiwara, Yasuhiro
    CANCER SCIENCE, 2017, 108 (05): : 987 - 994
  • [39] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
    Jacquet, E.
    Lardy-Cleaud, A.
    Pistilli, B.
    Franck, S.
    Cottu, P.
    Delaloge, S.
    Debled, M.
    Vanlemmens, L.
    Leheurteur, M.
    Guizard, A. V.
    Laborde, L.
    Uwer, L.
    Jacot, W.
    Berchery, D.
    Desmoulins, I.
    Ferrero, J. M.
    Perrocheau, G.
    Courtinard, C.
    Brain, E.
    Chabaud, S.
    Robain, M.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
  • [40] A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer
    Puglisi, Fabio
    Bisagni, Giancarlo
    Ciccarese, Mariangela
    Fontanella, Caterina
    Gamucci, Teresa
    Leo, Luigi
    Molino, Annamaria
    Silva, Rosa Rita
    Marchetti, Paolo
    FUTURE ONCOLOGY, 2016, 12 (22) : 2589 - 2602
12345